BioInvent International (BINV.ST) Stock Price
BioInvent International Price
Over the last 19 years BioInvent International grew revenue by 8.2% annually, reaching 226.50 M SEK. For BioInvent International, the net margin of -147.0% is up versus -1,439.1% a few years ago. The consensus 12-month price target for BioInvent International is 91.80 SEK, about 294.8% above where the stock trades today. Of 9 analysts, 8 rate the stock a buy — an overall Buy consensus.
BioInvent International stock price
BioInvent International business model & stock analysis
Frequently asked questions about BioInvent International
The business model of BioInvent International AB revolves around the discovery and development of innovative antibody-based immunotherapies. As a biopharmaceutical company, BioInvent focuses on identifying and targeting cancer and immune-mediated inflammatory diseases. Through its strong expertise in antibody research and proprietary antibody library, the company aims to develop novel drug candidates and partner with pharmaceutical companies for further clinical development and commercialization. By leveraging its unique technology platforms, BioInvent strives to provide effective and safe therapies to patients in need, while also generating value for its shareholders and partners.
BioInvent International AB is primarily active in the biotechnology industry.
The main competitors of BioInvent International AB in the market include other biotechnology companies that operate within the same therapeutic area and focus on the development of antibody-based therapeutics. Some notable competitors of BioInvent International AB may include Genmab A/S, MorphoSys AG, and Novartis AG. These competitors also strive to advance innovative solutions for diseases and disorders through research, development, and commercialization of antibody-based drugs. BioInvent International AB positions itself as a leading player in the field, continuously aiming to meet the evolving needs of patients and contribute to the growth of the biotech industry.
BioInvent International AB is a leading biotech company based in Sweden. Founded in 1987, BioInvent focuses on discovering and developing innovative antibody-based drugs for cancer treatment. With a rich history of over three decades, the company has gained expertise and recognition in the field of immuno-oncology. BioInvent collaborates with pharmaceutical partners to advance its proprietary antibody library, F.I.R.S.T™, and to accelerate the development of novel therapeutics. Through its innovative research and development efforts, BioInvent aims to improve patient outcomes and transform the treatment landscape for cancer. The company's commitment to scientific excellence and strategic partnerships has positioned it as a key player in the biopharmaceutical industry.
BioInvent International AB has achieved several significant milestones in its trajectory. The company successfully advanced its lead product candidate, BI-1206, into clinical trials. Furthermore, BioInvent International AB has established strategic collaborations with renowned pharmaceutical companies, including Pfizer and AstraZeneca, facilitating the development of innovative therapeutic antibodies. The company continues to demonstrate its commitment to research and development, expanding its pipeline and enhancing its expertise in the field of immuno-oncology. With a strong focus on strategic partnerships and an impressive track record, BioInvent International AB is well-positioned for future growth and success in the biopharmaceutical industry.
BioInvent International AB is primarily present in Sweden, where it is headquartered. As a biotech company, it focuses on the research and development of novel antibody-based drugs. Its operations encompass a global reach, collaborating with partners and clients across various countries and regions. However, in terms of primary presence and operations, BioInvent International AB is mainly concentrated in Sweden.
BioInvent International AB is a renowned biotech company committed to transforming the treatment of cancer. With a strong corporate philosophy focused on innovation and collaboration, BioInvent strives to deliver ground-breaking antibody-based therapies. The company's core values revolve around scientific excellence, integrity, and patient-centricity. BioInvent harnesses its unique antibody development platform to target and neutralize tumor antigens, leveraging its expertise in antibody engineering and immuno-oncology research. By prioritizing cutting-edge science and strategic partnerships, BioInvent seeks to address unmet medical needs and improve outcomes for cancer patients worldwide.
Analysts currently set an average price target of 81.60 SEK for the BioInvent International stock (median: 91.80 SEK), implying +251.0 % versus the latest price. The consensus is based on 9 analyst ratings.
9 analysts currently rate the BioInvent International stock: 8 recommend buying, 1 holding and 0 selling. For 2026, analysts expect BioInvent International to generate revenue of 275.64 M SEK and earnings per share of -7.03 SEK.
Converted at the current exchange rate, the BioInvent International share trades at 2.07 EUR (23.25 SEK).
The BioInvent International share (BINV.ST) is listed on 7 stock exchanges, including: London (0H22.L), Frankfurt (BIX0.F), München (BIX0.MU), Düsseldorf (BIX0.DU), Stockholm (BINV.ST).
BioInvent International AB is a biotechnology company based in Lund, Sweden, that focuses on the research and development of antibody therapies. The company's business model is based on the discovery, development, and commercialization of antibodies for the treatment of cancer and other serious diseases. BioInvent operates in three business areas - research and development, therapeutic antibody production and manufacturing, and collaboration and licensing. The company's products include the antibody therapies BI-505 and BI-1206. BI-505 is currently in Phase II studies for the treatment of multiple myeloma patients, and BI-1206 is currently in Phase I studies for the treatment of advanced solid tumors including lung, colorectal, and ovarian cancers. The company's business model is focused on developing innovative antibody therapies that meet the needs of cancer patients, and it works closely with partners to ensure rapid progress in research and development while meeting regulatory requirements. BioInvent is a leading company in the development of antibody therapies and has a promising future in expanding treatment options for cancer patients.
The expected revenue of BioInvent International is 275.64 M SEK. This figure is based on current financial data and reflects the company's business performance.
The expected profit of BioInvent International is -463.28 M SEK. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of BioInvent International is currently -3.31. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the BioInvent International stock.
The price-to-sales ratio (P/S) of BioInvent International is currently 5.56. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the BioInvent International stock.
The Eulerpool Quality Score for BioInvent International is 3/10.
The ISIN of BioInvent International is SE0015244520. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of BioInvent International is A2QJRW. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of BioInvent International is BINV.ST. The ticker symbol is used to trade BioInvent International shares on the stock exchange.
BioInvent International stock
BioInvent International Peer Group
BioInvent International Ticker
BioInvent International FIGI
All fundamentals and in-depth analysis of BioInvent International
Our stock analysis for BioInvent International stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of BioInvent International. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.